𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Medical treatment of Parkinson’s disease

✍ Scribed by Stanlex Fahn


Publisher
Springer
Year
1998
Tongue
English
Weight
90 KB
Volume
245
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Evidence-based medical review update: Ph
✍ Christopher G. Goetz; Werner Poewe; Olivier Rascol; Cristina Sampaio 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

## Abstract The objective of this study is to update a previous evidence‐based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January 2004 information. The __Movement__ Disorder Society (MDS) Task Force prepared an EBM review of PD treatments covering data up t

Prospective comparative study on cost-ef
✍ Francesc Valldeoriola; Ossama Morsi; Eduardo Tolosa; Jordi Rumià; Maria José Mar 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB

## Abstract This is an open, prospective, longitudinal study designed to compare two cohorts of patients with advanced Parkinson's disease during 1 year, one undergoing bilateral subthalamic stimulation (STN‐DBS) and the other receiving the best medical treatment (BMT), with respect to the clinical

Treatment results: Parkinson's disease
✍ Pierre Pollak; Valérie Fraix; Paul Krack; Elena Moro; Alexandre Mendes; Stephan 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Deep brain stimulation (DBS) is a neurosurgical treatment of Parkinson's disease that is applied to three targets: the ventral intermediate nucleus of the thalamus (Vim), the globus pallidus internas (GPi) and the subthalamic nucleus (STN). Vim DBS mainly improves contralateral tremor and, therefore

Suboptimal medication adherence in Parki
✍ Katherine A. Grosset; Ian Bone; Donald G. Grosset 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB

## Abstract Patients take less medication than prescribed in many disease areas but evidence for suboptimal therapy adherence in Parkinson's disease (PD) is limited. A single‐center observational study of antiparkinsonian medication was undertaken using electronic monitoring (MEMS; Aardex, Zug, Swi